Browsing Tag
Pfizer
118 posts
Can immunotherapy finally replace chemo in bladder cancer? Keytruda–Padcev combo shows the way
Explore how Merck’s Keytruda and Padcev combo is redefining bladder cancer treatment without chemo. Survival gains, sector impact, and what’s next in focus.
XOMA Royalty completes LAVA Therapeutics acquisition in push to strengthen bispecific antibody pipeline
Find out how XOMA Royalty’s acquisition of LAVA Therapeutics strengthens its oncology royalty portfolio and expands its partnered bispecific antibody programs.
Metsera picked Pfizer over Novo Nordisk — here’s what swung the $10bn deal
Pfizer secures obesity biotech Metsera for $10 billion after regulatory pushback sidelines Novo Nordisk. Find out what this means for pharma M&A now.
Why Pfizer’s $10bn Metsera deal could reshape the obesity drug market in 2026 and beyond
Pfizer beats Novo Nordisk in $10B Metsera buyout, reshaping obesity drug competition. Find out what this means for the pharma M&A and GLP-1 space.
Pfizer thought it secured Metsera—then Novo Nordisk crashed the party with a bigger bid
Novo Nordisk just challenged Pfizer’s Metsera deal with a $9B rival bid. Find out how this could reshape the weight-loss drug landscape in 2025.
Pfizer data reveal sustained survival with BRAFTOVI + MEKTOVI in rare lung cancer subtype
Find out how Pfizer’s BRAFTOVI + MEKTOVI combination is redefining survival for BRAF V600E-mutant lung cancer and what it means for Pfizer’s oncology strategy.
How AstraZeneca’s $4.5bn Virginia investment aligns with Trump-era tariffs and U.S. supply chain policy
Find out how AstraZeneca’s $4.5 billion Virginia API plant could reshape global pharma supply chains and investor sentiment in 2025.
Valneva slashes 2025 outlook after FDA suspends Ixchiq license, shaking investor confidence
Valneva slashes 2025 outlook after FDA suspends Ixchiq license—discover how the biotech aims to rebuild confidence and cash flow stability.
Enanta Pharmaceuticals to reveal Phase 2b RSV trial results—can zelicapavir change treatment for high-risk adults?
Enanta Pharmaceuticals will present Phase 2b zelicapavir results in RSV high-risk adults. See why this trial matters for investors, patients, and the RSV market.
AstraZeneca just joined the direct-to-consumer drug race — here’s what it means for patients and rivals
AstraZeneca launches AstraZeneca Direct in the U.S. with up to 70% discounts. Explore how this direct-to-consumer model could reshape drug access.